Khasanov, N. R. (2022). Empagliflozin: A path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations. «FIRMA «SILICEA» LLC.
Chicago Style (17th ed.) CitationKhasanov, N. R. Empagliflozin: A Path from Glycemic Control to Reduced Cardiovascular Mortality and Heart Failure-related Hospitalizations. «FIRMA «SILICEA» LLC, 2022.
MLA (9th ed.) CitationKhasanov, N. R. Empagliflozin: A Path from Glycemic Control to Reduced Cardiovascular Mortality and Heart Failure-related Hospitalizations. «FIRMA «SILICEA» LLC, 2022.
Warning: These citations may not always be 100% accurate.